

HEALEY ALS Platform Trial

Weekly Q&A – May 26, 2022




Healey Center

Sean M. Healey & AMG Center
for ALS at Mass General




The AMG Foundation

The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Study Results Timelines – Regimens A-D

***** Note: COVID-19 might impact these estimates**



LPLV

(Last Participant Last Visit in the Randomized,
Placebo Controlled Period)

Database Lock

Top Line Results

Study Reports

Expected Database Lock: July-Oct 2022

Top Line Results: Aug-Nov 2022

Study Reports: Nov-Dec 2022

Enrollment Updates (as of May 26, 2022)

- **64** individuals have signed informed consent
- **42** individuals have been randomized within Regimen E


Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

36 Sites Currently Activated for Regimen E



(as of 5/26/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

- ✓ Lehigh Valley Health Network
- ✓ UC San Francisco
- ✓ Mass General Hospital
- ✓ Mayo Rochester
- ✓ University of Kansas
- ✓ University of Washington
- ✓ University of Maryland
- ✓ California Pacific Medical Center
- ✓ Northwestern University
- ✓ Virginia Commonwealth University
- ✓ University of Nebraska
- ✓ Washington University
- ✓ Wake Forest University
- ✓ Hospital for Special Care
- ✓ Saint Alphonsus Regional
- ✓ University of Massachusetts
- ✓ Duke University
- ✓ Barrow Neurological Institute
- ✓ Georgetown University
- ✓ Texas Neurology
- ✓ Beth Israel Deaconess Medical Center
- ✓ SUNY Upstate
- ✓ Spectrum Health
- ✓ Henry Ford Hospital
- ✓ Essentia Health
- ✓ University of Southern California
- ✓ University of South Florida
- ✓ University of Colorado
- ✓ Providence Brain and Spine
- ✓ University of Minnesota
- ✓ Loma Linda University
- ✓ University of Iowa
- ✓ Swedish Medical Center
- ✓ Ohio State University
- ✓ University of Cincinnati
- ✓ Thomas Jefferson University

Regimen E Site Activation

Sites closest to activation:

- University of Pittsburgh
- Augusta University
- Vanderbilt University
- Indiana University
- Penn State Hershey

Checking Site Status Online

List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants in regimen E.

Sites marked "Active, Not recruiting" are active in the platform (for example, they are following participants in regimens A-D) but are not enrolling new participants at this time. Most active sites are expected to start enrolling in regimen E soon.

Site	State	Enrollment Status	Contact Information
Lehigh Valley Health Network	PA	Recruiting	Andrew Orzel (610-402-9543)
Penn State Hershey	PA	Active, Not recruiting	Heidi Runk



<https://bit.ly/3g2NZr5>

Patient Navigation

Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar
registration:



<https://bit.ly/3r6Nd2L>

ALS Link sign-up:



<https://bit.ly/3o2Ds3m>

Upcoming Guest Speakers:

June 2nd- Daniel Hevert (Lead Coordinator, Mass General Hospital)

June 9th- Honora Dalamagas and Natalie Cartwright (Hospital for Special Care)


June 16th- Bruce Rosenblum (EAP Patient Advisory Committee Member)



Allison Bulat

Send us webinar questions and ideas!


Travel around the
US meeting
Platform Trial Site
Investigators



Guest speakers
from partner
foundations

Trehalose/SLS-005
drug science and
mechanism of action
webinar with Seelos
Therapeutics

<https://bit.ly/3L4hrdB>



Special Topics:
Biomarkers, EAPs,
Biostats, Science
topics (epigenetics,
epidemiology)